Medistep Health.

Why is Medistep Healthcare Ltd falling/rising?

As of 01-Sep, Medistep Healthcare Ltd's stock price is rising to 21.00, up 2.19%, driven by strong short-term performance and increased investor participation, outperforming the Sensex and its sector. Despite being below the 200-day moving average, current trading liquidity is adequate.

As of 01-Sep, Medistep Healthcare Ltd's stock price is rising, currently at 21.00, reflecting an increase of 0.45 or 2.19%. This upward movement is supported by several factors. Over the past week, the stock has outperformed the Sensex, gaining 6.33% while the benchmark index fell by 1.15%. Similarly, in the last month, the stock has risen by 9.38%, contrasting with a decline of 1.34% in the Sensex.<BR><BR>Today's performance indicates that Medistep Healthcare Ltd has outperformed its sector by 2.79%. Additionally, there has been a notable increase in investor participation, with a delivery volume of 15,000 shares on August 31, which is up by 31.58% compared to the 5-day average. This suggests growing interest and confidence among investors in the stock.<BR><BR>While the stock is currently trading above its 5-day, 20-day, 50-day, and 100-day moving averages, it remains below the 200-day moving average, indicating a mixed long-term trend. However, the current liquidity is adequate for trading, as it represents 2% of the 5-day average traded value.<BR><BR>Overall, the combination of strong short-term performance, increased investor participation, and sector outperformance contributes to the rising stock price of Medistep Healthcare Ltd.

Which are the latest news on Medistep Health.?

What does Medistep Health. do?

Medistep Healthcare Ltd, a micro-cap company incorporated in June 2023, operates in the diversified consumer products industry and recently acquired M/s MG Pharma. As of June 2024, it reported net sales of 11 Cr and a net profit of 1 Cr, with a market cap of INR 28 Cr.

Overview:<BR>Medistep Healthcare Ltd operates in the diversified consumer products industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated on June 05, 2023, as a Public Limited Company. It subsequently acquired the business of M/s MG Pharma from one of its promoters, Ms. Prajapati Hetalben Girdharilal, through a business transfer agreement dated July 02, 2023. The latest quarterly results reported net sales and profit for June 2024.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 11 Cr (Quarterly Results - Jun 2024) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2024) <BR>Market-cap value: INR 28 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 5.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.12 <BR>Return on Equity: 15.81% <BR>Price to Book: 0.74 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Medistep Health.?

Medistep Health's peers include Archies, Aro Granite Inds, Oriental Trimex, Madhav Marbles, Lexus Granito, Pearl Polymers, SPP Polymer, SMVD Poly Pack, and Amin Tannery. Medistep Health shows good management risk and growth, while most peers exhibit below average performance in these areas, with SMVD Poly Pack having the highest 1-year return and Oriental Trimex the lowest.

Peers: The peers of Medistep Health are Archies, Aro Granite Inds, Oriental Trimex, Madhav Marbles, Lexus Granito, Pearl Polymers, SPP Polymer, SMVD Poly Pack, and Amin Tannery.<BR><BR>Quality Snapshot: Good management risk is observed at Medistep Health, while Below Average management risk is found at Archies, Aro Granite Inds, Madhav Marbles, Lexus Granito, Pearl Polymers, SPP Polymer, SMVD Poly Pack, and Amin Tannery. Excellent growth is noted at Medistep Health, while Below Average growth is seen at Archies, Aro Granite Inds, Madhav Marbles, Lexus Granito, Pearl Polymers, and Amin Tannery, and Average growth is found at Oriental Trimex and SPP Polymer. Good capital structure is present at Medistep Health, while Below Average capital structure is observed at Archies, Aro Granite Inds, Madhav Marbles, Lexus Granito, Pearl Polymers, and SMVD Poly Pack, and Average capital structure is noted at SPP Polymer.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SMVD Poly Pack at N/A, while the peer with the lowest 1-year return is Oriental Trimex at -45.44%. Medistep Health's 1-year return is -43.62%, which is slightly better than Oriental Trimex. Additionally, several peers, including Lexus Granito, Pearl Polymers, and Amin Tannery, have negative six-month returns.

How big is Medistep Health.?

As of 31st August, Medistep Healthcare Ltd has a market capitalization of 28.00 Cr, with recent net sales of 11.25 Cr and a net profit of 1.02 Cr for the quarter ending June 2024. The balance sheet as of March 2026 shows shareholder's funds of 37.82 Cr and total assets of 50.29 Cr.

As of 31st August, Medistep Healthcare Ltd has a market capitalization of 28.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest quarter ending June 2024, Medistep Healthcare Ltd reported Net Sales of 11.25 Cr and a Net Profit of 1.02 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, showing Shareholder's Funds of 37.82 Cr and Total Assets of 50.29 Cr.

Is Medistep Health. overvalued or undervalued?

As of November 13, 2025, Medistep Health is considered very attractive with a PE ratio of 9.37 and an EV to EBIT ratio of 6.86, significantly lower than its peers, indicating it is undervalued despite a strong recent weekly return of 21.88%.

As of 13 November 2025, the valuation grade for Medistep Health. has moved from does not qualify to very attractive. This indicates a significant improvement in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 9.37, an EV to EBIT ratio of 6.86, and a robust ROCE of 34.41%. <BR><BR>In comparison to its peers, Medistep Health. stands out with a much lower PE ratio than Sun Pharma (36.15) and Divi's Lab (70.4), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 6.82 is significantly more favorable than the industry averages, reinforcing its attractive valuation. While Medistep Health. has shown a strong weekly return of 21.88% compared to the Sensex's 1.45%, its longer-term performance metrics remain to be seen.

How has been the historical performance of Medistep Health.?

Medistep Health has shown significant growth over the past three years, with net sales increasing from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25, and profit after tax rising from 0.41 Cr to 4.14 Cr. The company has also improved its equity capital and cash flow management during this period.

Answer:<BR>The historical performance of Medistep Health shows significant growth over the past three years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Medistep Health's net sales increased from 7.46 Cr in Mar'23 to 31.62 Cr in Mar'24, and further to 49.65 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, rising from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25. The total expenditure also rose significantly from 6.87 Cr in Mar'23 to 44.06 Cr in Mar'25, reflecting the company's expansion efforts. Operating profit (PBDIT) improved from 0.59 Cr in Mar'23 to 5.59 Cr in Mar'25, while profit before tax rose from 0.55 Cr to 5.54 Cr in the same period. Profit after tax followed suit, increasing from 0.41 Cr in Mar'23 to 4.14 Cr in Mar'25. The company's equity capital grew from 1.07 Cr in Mar'23 to 10.47 Cr in Mar'25, and total liabilities increased from 14.95 Cr to 22.98 Cr. Cash flow from financing activities showed a net inflow of 1.00 Cr in Mar'25, compared to an outflow of 7.00 Cr in Mar'24, indicating improved cash management. Overall, Medistep Health has demonstrated robust growth in sales and profitability, alongside an increase in equity and total assets.